Want to track PSC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026
Mirum Pharmaceuticals, Inc. retains a Buy rating, supported by positive interim analyses for VOLIXIBAT in both PBC [VANTAGE] and PSC [VISTAS] phase 2b trials. Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its balance sheet with $200M gross proceeds from Bluejay Therapeutics acquisition and private placements, plus a $68.5M TCGX placement agreement.
Seekingalpha | 6 months ago
